Our phase I study examining the addition of certolizumab, an anti-TNF-α monoclonal antibody, to cisplatin and pemetrexed chemotherapy in patients with untreated stage IV lung adenocarcinoma demonstrated that this intervention is feasible, well-tolerated, and has a promising efficacy signal. This evidence concerns the gene TNF and lung adenocarcinoma.